1. Home
  2. ADT vs RYTM Comparison

ADT vs RYTM Comparison

Compare ADT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADT Inc.

ADT

ADT Inc.

N/A

Current Price

$9.90

Market Cap

7.2B

ML Signal

N/A

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

N/A

Current Price

$113.18

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADT
RYTM
Founded
1874
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
6.3B
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
ADT
RYTM
Price
$9.90
$113.18
Analyst Decision
Hold
Strong Buy
Analyst Count
4
19
Target Price
$10.00
★ $139.76
AVG Volume (30 Days)
★ 25.0M
1.8M
Earning Date
11-03-2026
11-03-2026
Dividend Yield
★ 2.23%
N/A
EPS Growth
★ 29.63
28.34
EPS
★ N/A
N/A
Revenue
★ $5,128,607,000.00
N/A
Revenue This Year
$2.35
$74.20
Revenue Next Year
$2.26
$74.91
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 4.70
N/A
52 Week Low
$6.03
$74.50
52 Week High
$10.00
$122.20

Technical Indicators

Market Signals
Indicator
ADT
RYTM
Relative Strength Index (RSI) 83.14 57.97
Support Level $6.26 $100.33
Resistance Level $9.94 N/A
Average True Range (ATR) 0.03 8.32
MACD -0.07 0.91
Stochastic Oscillator 55.00 79.72

Price Performance

Historical Comparison
ADT
RYTM

About ADT ADT Inc.

ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: